Metabolic · In Clinical Trials
Efinopegdutide
No lawful US pathway
01 · Overview
Efinopegdutide (MK-6024) is a long-acting dual agonist of the GLP-1 and glucagon receptors given once weekly by subcutaneous injection. The compound combines GLP-1-mediated glycemic control and appetite reduction with glucagon receptor activity that may act directly on the liver to promote fatty acid oxidation and reduce fat synthesis (PMID 37355043).
It is under investigation mainly for metabolic dysfunction-associated steatotic liver disease and steatohepatitis.
02 · Research summary & key findings
In a 24-week phase 2a open-label trial in 145 adults with non-alcoholic fatty liver disease, efinopegdutide reduced liver fat content by 72.7 percent versus 42.3 percent with semaglutide (PMID 37355043). Body weight fell by 8.5 percent with efinopegdutide and 7.1 percent with semaglutide, a difference that was not statistically significant (PMID 37355043). Gastrointestinal adverse events were somewhat more frequent with efinopegdutide than with semaglutide (PMID 37355043).
03 · Regulatory status
Efinopegdutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Efinopegdutide is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Metabolic
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Efinopegdutide is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease J Hepatol, 2023. PMID 37355043
Primary literature
- PubMed: "Efinopegdutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Efinopegdutide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Efinopegdutide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.